文献速递妇科

明智选择:选择PARP抑制剂联合方案以促进BRCA突变之外的抗肿瘤免疫应答

Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
PubMed 文献 · Gynecol Oncol · 2019-10-17

综述讨论PARP抑制剂在晚期高级别浆液性卵巢癌中的应用局限,包括原发性与获得性耐药、PARP抑制剂后管理及无BRCA突变人群的适用性问题,并探讨PARP抑制剂联合方案的生物学依据与选择。

要点

  • PARP抑制剂已改变晚期高级别浆液性卵巢癌的治疗格局,尤其在BRCA突变患者中。
  • PARP抑制剂用于更早期治疗时,原发性和获得性耐药及PARP抑制剂后管理成为紧迫问题。
  • 无BRCA突变患者使用PARP抑制剂的适用人群存在争议且仍在演变。

核心结论

  • 综述讨论PARP抑制剂联合方案的生物学依据与选择,以促进BRCA突变之外的抗肿瘤免疫应答。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • PARP抑制剂已改变晚期高级别浆液性卵巢癌的管理。
  • PARP抑制剂用于更早期治疗时,原发性和获得性耐药机制及PARP抑制剂后管理是紧迫问题。
  • 无BRCA突变患者使用PARP抑制剂的适用人群存在争议且仍在演变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. With PARP inhibitors now being used in earlier treatment settings, the issue of both de novo and acquired resistance mechanisms and appropriate post-PARP management are pressing concerns. In addition, the population appropriate to target with PARP inhibitors and their use in patients without BRCA mutations is controversial and evolving. In this review we will discuss exciting PARP combinations and biologic rationale for the development and selection of PARP inhibitor combinations.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Veneris JT, Matulonis UA, Liu JF, et al. Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecol Oncol. 2019. PMID: 31630846. doi:10.1016/j.ygyno.2019.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。